12:00 AM
 | 
Oct 04, 2010
 |  BioCentury  |  Emerging Company Profile

Integrated Diagnostics: Multiplexed detection

Integrated Diagnostics: Blood-based proteomic tests to detect early stage disease

Integrated Diagnostics Inc. is developing diagnostics that measure the levels of hundreds of proteins in blood simultaneously to detect early stage diseases. The company initially plans to translate its extensive academic partnerships into clinical tests for lung cancer and Alzheimer's disease, where current diagnostic procedures are inadequate, invasive or impractical.

Most blood diagnostics are antibody-based and detect a limited number of proteins, which in turn limits their predictive power.

"While there are many tests that work well by measuring levels of one protein, in many indications, including cancer and diabetes, you really can't assess the state of the disease with such a limited set of markers," President, CSO and co-founder Paul Kearny told BioCentury.

Integrated Diagnostics solves this problem by using a mass spectroscopy technology known as multiple reaction monitoring (MRM), which detects hundreds of proteins simultaneously at low cost. The technology has been used in large-scale marker discovery by many labs in the...

Read the full 755 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >